BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rizzo A, Ricci AD, Brandi G. IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver? Cancer Treat Res Commun 2021;27:100356. [PMID: 33799004 DOI: 10.1016/j.ctarc.2021.100356] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Moris D, Palta M, Kim C, Allen PJ, Morse MA, Lidsky ME. Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians. CA Cancer J Clin 2022. [PMID: 36260350 DOI: 10.3322/caac.21759] [Reference Citation Analysis]
2 Cheng C, Chen C, Wu C. Precision Medicine in Cholangiocarcinoma: Past, Present, and Future. Life 2022;12:829. [DOI: 10.3390/life12060829] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Haapala I, Kondratev A, Roine A, Mäkelä M, Kontunen A, Karjalainen M, Laakso A, Koroknay-pál P, Nordfors K, Haapasalo H, Oksala N, Vehkaoja A, Haapasalo J. Method for the Intraoperative Detection of IDH Mutation in Gliomas with Differential Mobility Spectrometry. Current Oncology 2022;29:3252-8. [DOI: 10.3390/curroncol29050265] [Reference Citation Analysis]
4 Chung T, Park YN. Up-to-Date Pathologic Classification and Molecular Characteristics of Intrahepatic Cholangiocarcinoma. Front Med 2022;9:857140. [DOI: 10.3389/fmed.2022.857140] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Krenzien F, Nevermann N, Krombholz A, Benzing C, Haber P, Fehrenbach U, Lurje G, Pelzer U, Pratschke J, Schmelzle M, Schöning W. Treatment of Intrahepatic Cholangiocarcinoma-A Multidisciplinary Approach. Cancers (Basel) 2022;14:362. [PMID: 35053523 DOI: 10.3390/cancers14020362] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
6 Sumbly V, Landry I, Rizzo V. Ivosidenib for IDH1 Mutant Cholangiocarcinoma: A Narrative Review. Cureus 2022. [DOI: 10.7759/cureus.21018] [Reference Citation Analysis]
7 Baretti M, Azad NS. Epigenetic therapy and DNA damage response. Epigenetics and DNA Damage 2022. [DOI: 10.1016/b978-0-323-91081-1.00009-1] [Reference Citation Analysis]
8 Aleksakhina SN, Imyanitov EN. Cancer Therapy Guided by Mutation Tests: Current Status and Perspectives. Int J Mol Sci 2021;22:10931. [PMID: 34681592 DOI: 10.3390/ijms222010931] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
9 Anichini G, Carrassa L, Stecca B, Marra F, Raggi C. The Role of the Hedgehog Pathway in Cholangiocarcinoma. Cancers (Basel) 2021;13:4774. [PMID: 34638259 DOI: 10.3390/cancers13194774] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
10 Rizzo A. Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors. Medicina (Kaunas) 2021;57:458. [PMID: 34066684 DOI: 10.3390/medicina57050458] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]